Clinical trials: Checkpoint Inhibitor, open to volunteers
Checkpoint Inhibitor, Pilot Study
Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study
To find out if taking a drug called infliximab (the "study drug") is safe and effective in reversing insulin dependence in CIADM.
- Conditions
- Checkpoint Inhibitor, Pilot Study, Diabetes Melletus
- Trial name
- NCT07257068
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
The Phase II NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with cisplatin based neoadjuvant chemotherapy in a clinical practice setting.
- Conditions
- Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
- Trial name
- NCT06960577
- Testing
- Durvalumab, Methotrexate, Vinblastine
- Where
- 59 sites in Australia, Brazil and 5 more
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
mRNA Vaccination, Hepatocellular Carcinoma
SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors
A multicenter retrospective cohort analysis in Austria Primary Objective: To assess whether receiving an mRNA COVID-19 vaccine within 3 months before starting ICI (Immune checkpoint inhibitors) therapy improves best overall…
- Conditions
- mRNA Vaccination, Hepatocellular Carcinoma, Checkpoint Inhibitor
- Trial name
- CoVaCheck (NCT07341321)
- Where
- 5 sites in Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Graz
Arthritis, Polymyalgia Rheumatica
A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
- Conditions
- Arthritis, Polymyalgia Rheumatica, Immune Checkpoint Inhibitors
- Trial name
- NCT06647134
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Borderline Resectable Carcinoma, Unresectable Cancer
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
Esophageal cancer (EC) ranks among the leading malignant gastrointestinal tumors globally in terms of both incidence and mortality.
- Conditions
- Borderline Resectable Carcinoma, Unresectable Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Immune Checkpoint Inhibitor
- Trial name
- ILDR-03 (NCT07339488)
- Testing
- Intestinal Low Dose Radiotherapy-1Gy, PD-1/PD-L1 inhibitors, Chemotherapy
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Chuangzhen Chen
Breast Cancer, Neoadjuvant Therapy
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
Iparomlimab and Tuvonralimab Injection (QL1706) is a bifunctional combination antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4).
- Conditions
- Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors, QL1706
- Trial name
- NCT07372079
- Testing
- QL1706 combined with Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Immune Checkpoint Inhibitor-related Rash, Immune-related Adverse Events
Wucao Anfu Formula as Adjunctive Treatment for Immune Checkpoint Inhibitor-Related Rash
Immune checkpoint inhibitors have improved outcomes for patients with cancer, but immune checkpoint inhibitor-related skin rash is a common adverse event that may affect quality of life and continuation of anticancer therapy.
- Trial name
- NCT07821424
- Testing
- Wucao Anfu Formula, Standard management
- Volunteers
- 72 people
- Sponsor
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Lung Cancer, Rechallenge
PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
This multicenter observational study will evaluate the safety and effectiveness of immune checkpoint inhibitor rechallenge in adults with lung cancer who developed checkpoint inhibitor pneumonitis.
- Conditions
- Lung Cancer, Rechallenge, Checkpoint Inhibitor Pneumonitis
- Trial name
- NCT07775820
- Testing
- PD-L1 Inhibitor Rechallenge, PD-1 Inhibitor Rechallenge, No Immune Checkpoint Inhibitor Rechallenge
- Where
- 5 sites in China
- Volunteers
- 150 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Non-Small Cell Lung Cancer, Adjuvant Therapy
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
This multicenter, randomized, open-label, phase II trial is designed to evaluate the efficacy and safety of adjuvant sintilimab in patients with completely resected non-small cell lung cancer who remain at high risk of recurrence…
- Conditions
- Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- RICA (NCT07748325)
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sichuan University
Triple Negative Breast Cancer, Immune Checkpoint Inhibitor
Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
This study plans to enroll 30 patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who are scheduled to receive at least two cycles of a regimen containing an immune checkpoint inhibitor (ICI).
- Conditions
- Triple Negative Breast Cancer, Immune Checkpoint Inhibitor, Granzyme B PET/CT
- Trial name
- NCT07705438
- Testing
- [68Ga]Ga-DOTA-GSI PET/CT (Granzyme B PET/CT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Endometrial Cancer, Immune Checkpoint Inhibitors
DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER
In recent years, the introduction of immune checkpoint inhibitors (ICI) in combination with chemotherapy has significantly changed the management of advanced and recurrent Endometrial Cancer (EC).
- Trial name
- iDEA (NCT07690540)
- Testing
- Prospective exploratory cohort
- Where
- Italy
- Volunteers
- 510 people
- Sponsor
- European Institute of Oncology
Locally Advanced Non-small Cell Lung Cancer (NSCLC), Thoracic Radiotherapy
Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response
Lattice radiation therapy (LRT) is a spatially fractionated thoracic radiotherapy technique that creates alternating high- and low-dose regions within primary lung tumors and metastatic lymph nodes to strengthen local tumor…
- Conditions
- Locally Advanced Non-small Cell Lung Cancer (NSCLC), Thoracic Radiotherapy, Immune Checkpoint Inhibitors, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT07670715
- Testing
- lattice radiation therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Neoplasms, Drug Therapy
Analysis of Efficacy and Outcomes of Immunotherapy for Malignant Tumors: A Prospective Non-interventional Clinical Study
The population receiving immunotherapy is heterogeneous. Multiple factors, including combination treatment modalities, influence the immune response, and survival outcomes also vary among individuals receiving immunotherapy.
- Conditions
- Neoplasms, Drug Therapy, Immune Checkpoint Inhibitors (ICIs)
- Trial name
- NCT07665697
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Sichuan University
Radiotherapy, Immune Checkpoint Inhibitors (ICIs)
Real-world Study on the Efficacy, Safety, and Prognostic Factors of Immune Checkpoint Inhibitors Combined With Radiotherapy in Patients With Malignant Tumors: A Prospective Non-interventional Clinical Study
Currently, chemotherapy, targeted therapy, immunotherapy, and radiotherapy are the core treatment modalities for malignant tumors, with technologies advancing rapidly.
- Trial name
- NCT07665736
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sichuan University
Liver Injury, Secondary to Immune Checkpoint Inhibitors
Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis
Background and Study Rationale Immune checkpoint inhibitors (ICI) are a breakthrough cancer treatment that boosts the immune system to fight tumors.
- Conditions
- Liver Injury, Secondary to Immune Checkpoint Inhibitors, Cancer Patients
- Trial name
- CO-CHILI (NCT06864481)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Montpellier
Arrhythmia, Long QT Syndrome
AI-powered ECG Analysis for Deadly Arrhythmias and ICI Myocarditis
ELDORA is a non-interventional observational data-science study aiming to develop and validate clinical-grade artificial intelligence tools applied to electrocardiogram (ECG) data.
- Conditions
- Arrhythmia, Long QT Syndrome, Immune Checkpoint Inhibitor-Related Myocarditis
- Trial name
- ELDORA (NCT07644715)
- Where
- France
- Volunteers
- 127,000 people, healthy volunteers welcome
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Melanoma, Immune-related Adverse Event
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
Primary Objective: To evaluate the effectiveness of Thymosin Alpha-1 combined with PD-1 monoclonal antibody in elderly patients with advanced melanoma .
- Conditions
- Melanoma, Immune-related Adverse Event, Immune Checkpoint Inhibitor
- Trial name
- NCT07644897
- Testing
- Thymosin Alpha 1 and Anti-PD-1 monoclonal antibody
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University
Immune Checkpoint Inhibitor-associated Myocarditis
ATROPOS: Survival Analysis of ICI-associated Myocarditis
ATROPOS is an international, registry-based observational study of cancer patients with immune checkpoint inhibitor-associated myocarditis (ICI-M).
- Trial name
- ATROPOS (NCT07633587)
- Where
- France
- Volunteers
- 1,500 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Immune Checkpoint Inhibitor-Related Pneumonitis, Drug-Related Side Effects and Adverse Reactions
Nutritional + Usual Corticosteroids Randomized Trial for Immune-Related pneumoniA - Therapeutic Utilization Evaluation
This is a prospective, single-center, open-label, randomized controlled clinical trial evaluating whether the addition of a nutritional therapy regimen (Spirulina-Bifidobacterium capsules, fish oil-grape seed-blueberry soft…
- Conditions
- Immune Checkpoint Inhibitor-Related Pneumonitis, Drug-Related Side Effects and Adverse Reactions, Neoplasms
- Trial name
- NCT07554885
- Testing
- Spirulina-Bifidobacterium capsule, Fish oil-grape seed-blueberry soft capsule, Ganoderma spore oil
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Pneumonitis, Interstitial, Immune Checkpoint Inhibitors (ICIs)
Exploratory Study on the Efficacy and Safety of Nebulized hUC-MSC-Derived Exosomes for Non-Acute CIP
Study Objectives The primary objective of Phase II is to evaluate the percentage of lesion resolution on high-resolution computed tomography (HRCT) as assessed by independent blinded reviewers.
- Conditions
- Pneumonitis, Interstitial, Immune Checkpoint Inhibitors (ICIs), Mesenchymal Stem Cells, Exosomes
- Trial name
- NCT07599111
- Testing
- Nebulized hUCMSC-Exos, Nebulized normal saline
- Volunteers
- 40 people
- Sponsor
- Zhou Chengzhi